E Fund Management Co. Ltd. Purchases Shares of 21,300 BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Key Points

• E Fund Management Co. Ltd. invested approximately $1.94 million in BioNTech SE, acquiring 21,300 shares during the first quarter.
• BioNTech reported earnings of ($1.60) per share for the last quarter, missing estimates, but its revenue increased by 102.6% year-over-year to $306.46 million.
• Analysts show optimism for BioNTech, with Bank of America raising its price target to $134.00, while the stock has an average rating of "Moderate Buy" and a consensus price target of $135.91.

E Fund Management Co. Ltd. bought a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,300 shares of the company's stock, valued at approximately $1,940,000.

Other large investors have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC purchased a new position in shares of BioNTech during the first quarter worth about $288,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of BioNTech during the fourth quarter worth about $238,000. GAMMA Investing LLC boosted its stake in shares of BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after buying an additional 52,711 shares during the period. Allianz Asset Management GmbH boosted its stake in shares of BioNTech by 44.3% during the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock worth $10,989,000 after buying an additional 37,075 shares during the period. Finally, Cerity Partners LLC acquired a new stake in shares of BioNTech during the first quarter worth about $357,000. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Price Performance

Shares of BioNTech stock traded up $0.82 during trading on Friday, hitting $113.52. 501,363 shares of the company were exchanged, compared to its average volume of 694,543. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $131.49. The stock has a market capitalization of $27.29 billion, a price-to-earnings ratio of -70.95 and a beta of 1.23. The firm has a 50 day moving average price of $109.42 and a 200 day moving average price of $105.81.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.41) by ($0.19). The company had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%. The company's revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($3.36) earnings per share. On average, equities analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BNTX shares. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the stock an "overweight" rating in a research note on Tuesday, August 5th. Truist Financial reiterated a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. Wall Street Zen upgraded shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.